# A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

> **NCT00338286** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 2098 (actual)

## Conditions studied

- Breast Cancer
- Neoplasm Metastasis

## Interventions

- **OTHER:** Standard supportive care (packed RBC transfusion)
- **DRUG:** epoetin alfa + packed RBC transfusion

## Key facts

- **NCT ID:** NCT00338286
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03-02
- **Primary completion:** 2014-07-07
- **Final completion:** 2017-01-31
- **Target enrollment:** 2098 (ACTUAL)
- **Last updated:** 2018-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00338286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00338286, "A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00338286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*